These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 12904067

  • 21. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs.
    Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J.
    Acta Pol Pharm; 2008; 65(3):307-18. PubMed ID: 18646550
    [Abstract] [Full Text] [Related]

  • 22. Kohonen maps for prediction of binding to human cytochrome P450 3A4.
    Balakin KV, Ekins S, Bugrim A, Ivanenkov YA, Korolev D, Nikolsky YV, Skorenko AV, Ivashchenko AA, Savchuk NP, Nikolskaya T.
    Drug Metab Dispos; 2004 Oct; 32(10):1183-9. PubMed ID: 15231683
    [Abstract] [Full Text] [Related]

  • 23. Cytochrome P450-catalyzed pathways in human brain: metabolism meets pharmacology or old drugs with new mechanism of action?
    Haining RL, Nichols-Haining M.
    Pharmacol Ther; 2007 Mar; 113(3):537-45. PubMed ID: 17270273
    [Abstract] [Full Text] [Related]

  • 24. Early prediction of drug metabolism and toxicity: systems biology approach and modeling.
    Bugrim A, Nikolskaya T, Nikolsky Y.
    Drug Discov Today; 2004 Feb 01; 9(3):127-35. PubMed ID: 14960390
    [Abstract] [Full Text] [Related]

  • 25. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
    Lewis DF, Jacobs MN, Dickins M.
    Drug Discov Today; 2004 Jun 15; 9(12):530-7. PubMed ID: 15183161
    [Abstract] [Full Text] [Related]

  • 26. In silico site of metabolism prediction of cytochrome P450-mediated biotransformations.
    Tarcsay Á, Keseru GM.
    Expert Opin Drug Metab Toxicol; 2011 Mar 15; 7(3):299-312. PubMed ID: 21291341
    [Abstract] [Full Text] [Related]

  • 27. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3.
    van Vugt-Lussenburg BM, Damsten MC, Maasdijk DM, Vermeulen NP, Commandeur JN.
    Biochem Biophys Res Commun; 2006 Aug 04; 346(3):810-8. PubMed ID: 16777067
    [Abstract] [Full Text] [Related]

  • 28. QSAR of cytochrome inhibitors.
    Roy K, Roy PP.
    Expert Opin Drug Metab Toxicol; 2009 Oct 04; 5(10):1245-66. PubMed ID: 19708826
    [Abstract] [Full Text] [Related]

  • 29. Site of metabolism prediction for six biotransformations mediated by cytochromes P450.
    Zheng M, Luo X, Shen Q, Wang Y, Du Y, Zhu W, Jiang H.
    Bioinformatics; 2009 May 15; 25(10):1251-8. PubMed ID: 19286831
    [Abstract] [Full Text] [Related]

  • 30. Probing the world of cytochrome P450 enzymes.
    Frye RF.
    Mol Interv; 2004 Jun 15; 4(3):157-62. PubMed ID: 15210869
    [Abstract] [Full Text] [Related]

  • 31. Structure-based versus property-based approaches in the design of G-protein-coupled receptor-targeted libraries.
    Balakin KV, Lang SA, Skorenko AV, Tkachenko SE, Ivashchenko AA, Savchuk NP.
    J Chem Inf Comput Sci; 2003 Jun 15; 43(5):1553-62. PubMed ID: 14502489
    [Abstract] [Full Text] [Related]

  • 32. Cytochrome P450 enzymes and genotype-guided drug therapy.
    Roederer MW.
    Curr Opin Mol Ther; 2009 Dec 15; 11(6):632-40. PubMed ID: 20072940
    [Abstract] [Full Text] [Related]

  • 33. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P, Kubiak-Tomaszewska G, Łukaszkiewicz J, Pachecka J.
    Acta Pol Pharm; 2008 Dec 15; 65(3):319-29. PubMed ID: 18646551
    [Abstract] [Full Text] [Related]

  • 34. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.
    Dong D, Wu B.
    Drug Metab Rev; 2012 Feb 15; 44(1):1-17. PubMed ID: 22242930
    [Abstract] [Full Text] [Related]

  • 35. Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3.
    Stjernschantz E, van Vugt-Lussenburg BM, Bonifacio A, de Beer SB, van der Zwan G, Gooijer C, Commandeur JN, Vermeulen NP, Oostenbrink C.
    Proteins; 2008 Apr 15; 71(1):336-52. PubMed ID: 17957765
    [Abstract] [Full Text] [Related]

  • 36. Skin permeation rate as a function of chemical structure.
    Katritzky AR, Dobchev DA, Fara DC, Hür E, Tämm K, Kurunczi L, Karelson M, Varnek A, Solov'ev VP.
    J Med Chem; 2006 Jun 01; 49(11):3305-14. PubMed ID: 16722649
    [Abstract] [Full Text] [Related]

  • 37. Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates.
    Balakin KV, Ekins S, Bugrim A, Ivanenkov YA, Korolev D, Nikolsky YV, Ivashchenko AA, Savchuk NP, Nikolskaya T.
    Drug Metab Dispos; 2004 Oct 01; 32(10):1111-20. PubMed ID: 15269187
    [Abstract] [Full Text] [Related]

  • 38. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries.
    Chohan KK, Paine SW, Mistry J, Barton P, Davis AM.
    J Med Chem; 2005 Aug 11; 48(16):5154-61. PubMed ID: 16078835
    [Abstract] [Full Text] [Related]

  • 39. In silico human and rat Vss quantitative structure-activity relationship models.
    Gleeson MP, Waters NJ, Paine SW, Davis AM.
    J Med Chem; 2006 Mar 23; 49(6):1953-63. PubMed ID: 16539383
    [Abstract] [Full Text] [Related]

  • 40. Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions.
    Zernov VV, Balakin KV, Ivaschenko AA, Savchuk NP, Pletnev IV.
    J Chem Inf Comput Sci; 2003 Mar 23; 43(6):2048-56. PubMed ID: 14632457
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.